(NASDAQ: RPTX) Repare Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.6%.
Repare Therapeutics's earnings in 2025 is -$84,689,000.On average, 2 Wall Street analysts forecast RPTX's earnings for 2025 to be -$104,151,235, with the lowest RPTX earnings forecast at -$118,604,875, and the highest RPTX earnings forecast at -$89,697,594. On average, 1 Wall Street analyst forecast RPTX's earnings for 2026 to be -$72,693,311, with the lowest RPTX earnings forecast at -$72,693,311, and the highest RPTX earnings forecast at -$72,693,311.
In 2027, RPTX is forecast to generate -$40,810,280 in earnings, with the lowest earnings forecast at -$40,810,280 and the highest earnings forecast at -$40,810,280.